Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

NCT01877083 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01877083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01877083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 5, 2013
Completion date
November 2, 2017
Enrollment
25 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

kif5b-ret-positive adenocarcinoma of the lung